BNTC vs. ZYME, ADPT, GYRE, PSTX, OCS, NUVB, AVXL, ABCL, CVAC, and AVBP
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Zymeworks (ZYME), Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Oculis (OCS), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), CureVac (CVAC), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.
Benitec Biopharma vs.
Zymeworks (NYSE:ZYME) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.
Benitec Biopharma has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Benitec Biopharma's return on equity.
Benitec Biopharma has lower revenue, but higher earnings than Zymeworks.
Zymeworks has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
Zymeworks received 98 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 67.75% of users gave Zymeworks an outperform vote while only 65.32% of users gave Benitec Biopharma an outperform vote.
Zymeworks presently has a consensus target price of $19.17, suggesting a potential upside of 38.09%. Benitec Biopharma has a consensus target price of $24.43, suggesting a potential upside of 137.17%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Zymeworks.
In the previous week, Zymeworks had 7 more articles in the media than Benitec Biopharma. MarketBeat recorded 9 mentions for Zymeworks and 2 mentions for Benitec Biopharma. Zymeworks' average media sentiment score of 1.08 beat Benitec Biopharma's score of 0.95 indicating that Zymeworks is being referred to more favorably in the media.
92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Comparatively, 1.3% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Zymeworks beats Benitec Biopharma on 10 of the 17 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:BNTC) was last updated on 1/18/2025 by MarketBeat.com Staff
Free BNTC Stock Alerts